The short version of HPLC-MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-17 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Over 10,000 people attended the monument's unveiling in September 1997. In the following months it was vandalised several times; in one instance it was daubed with the letters "AWB", an acronym of the Afrikaner Weerstandsbeweging, a far-right Afrikaner paramilitary group. In 1997, the cemetery where Biko was buried was renamed the Steve Biko Garden of Remembrance. The District Six Museum also held an exhibition of artwork marking the 20th anniversary of his death by examining his legacy. Also in September 1997, Biko's family established the Steve Biko Foundation. The Ford Foundation donated money to the group to establish a Steve Biko Centre in Ginsberg, opened in 2012. The Foundation launched its annual Steve Biko Memorial Lecture in 2000, each given by a prominent black intellectual. The first speaker was Njabulo Ndebele; later speakers included Zakes Mda, Chinua Achebe, Ngũgĩ wa Thiong'o, and Mandela. Buildings, institutes and public spaces around the world have been named after Biko, such as the Steve Bikoplein in Amsterdam. In 2008, the Pretoria Academic Hospital was renamed the Steve Biko Hospital. The University of the Witwatersrand has a Steve Biko Centre for Bioethics. In Salvador, Bahia, a Steve Biko Institute was established to promote educational attainment among poor Afro-Brazilians. In 2012, the Google Cultural Institute published an online archive containing documents and photographs owned by the Steve Biko Foundation. On 18 December 2016, Google marked what would have been Biko's 70th birthday with a Google Doodle.
=== From human single-domain antibodies === Humans occasionally produce single domain antibodies by the random creation of a stop codon in the light chain. Human single-domain antibodies targeting various tumor antigens including mesothelin, GPC2 and GPC3 were isolated by phage display. The HN3 human single-domain antibodies have been used to create immunotoxins and chimeric antigen receptor (CAR) T cells for treating liver cancer. Blocking the Wnt binding domain of GPC3 by the HN3 human single-domain antibody inhibits Wnt activation in liver cancer cells.
The transpiration and growth of the mushroom were heavily influenced by the humidity of the air, and the transpiration was accelerated at higher humidities while light did not affect the growth. Faster growth was observed at higher humidities. It was also discovered that misting enhanced both the growth and transpiration rates in the growing process of P. cubensis.
Sources: en.wikipedia.org
In April 2023, President Lula began his four-day trip during which he called Portugal relations with Brazil "extraordinary" and stated that "Portugal is not simply a foreign country but our home extension". In the 13th Brazil-Portugal Summit the countries signed several agreements such as a mutual recognition of professional degrees, driver's licenses, rights of persons with disabilities and a witness protection programme in both countries. Other agreements signed during the visit include education, science, tourism, energy and audiovisual areas. Lula also attended a high-level Brazilian-Portuguese business meeting in Matosinhos in which Brazilian aerospace giant Embraer and four Portuguese companies (OGMA, EMPORDEF, GMVIS Skysof and CEiiA) announced a deal to build a Brazilian-designed aircraft. Also in the meeting, Prime Minister António Costa announced Portugal companies EDP and Galp will be investing a total of €5.7 billion in projects in Brazil over the next years. On 24 April, Lula took part in a ceremony at the Queluz Palace to award Brazilian singer and songwriter Chico Buarque the Camões Prize.
Using purified proteins on substrates including artificial lipid bilayers and flow-based adhesion assays, his lab discovered the first heterophilic (like-unlike) receptor–counter-receptor adhesion pairs in all of cell biology, including CD2–LFA-3 and LFA-1–ICAM. The LFA-1–ICAM interaction required Mg2+, and explained the Mg2+-dependence of cell adhesion in antigen recognition. Subsequently, Springer structurally resolved the LFA-1–ICAM-1 interaction, with Mg2+ at the ligand-binding interface.
In 2005, it launched an original property of its creation, Brothers in Arms, with the release of Brothers in Arms: Road to Hill 30 on the Xbox, PC and PlayStation 2. Later that year a sequel, Brothers in Arms: Earned in Blood, was launched. In 2008, Brothers in Arms: Hell's Highway was released. 2007 brought announcements of new projects based on licensed film intellectual properties, including the crime drama Heat and the science-fiction classic Aliens. In the September 2007 issue of Game Informer, Pitchford stated that development on the Heat game had not yet begun, as the planned development partner for the project had gone under. This was followed by an announcement by Sega that it would be helming a new version of rhythm game Samba de Amigo for the Wii, a departure from its signature first-person shooter titles.
Sources: en.wikipedia.org
=== Nonsteroidal anti-inflammatory drugs === Although individual analgesics rarely induce liver damage due to their widespread use, NSAIDs have emerged as a major group of drugs exhibiting hepatotoxicity. Both dose-dependent and idiosyncratic reactions have been documented. Aspirin and phenylbutazone are associated with intrinsic hepatotoxicity; idiosyncratic reaction has been associated with ibuprofen, sulindac, phenylbutazone, piroxicam, diclofenac and indomethacin.
=== Travel distances === Teams participating in the 2026 World Cup had to travel an average of 5,146 total miles (8,281.7 km) between venues during the tournament. For the 2014 tournament in Brazil, the average distance was 7,054 miles (11,352.2 km), while teams playing in the 2018 tournament in Russia traveled an average of 5,441 miles (8,756.4 km).
==== Comparing molecular fingerprints ==== To search in a molecular structure database requires a metric to compare and score the molecular fingerprints. Tanimoto similarity (Jaccard index) is a commonly employed metric. A similarity value of 1 signifies identical fingerprints, while a value of 0 indicates structures that do not share any molecular properties. The calculated similarity value depends on the choice of fingerprint type. CSI:FingerID employs a logarithmic posterior probability to rank the structure candidates, where scores are represented as negative numbers, and zero is the optimum. This scoring function results in a higher number of correct identifications. Tanimoto similarities are also given.
Ideology, values or interests Applied, empirical or synthesis research Theoretical or academic research According to the National Institute for Research Advancement, a Japanese policy institute, think tanks are "one of the main policy actors in democratic societies ..., assuring a pluralistic, open and accountable process of policy analysis, research, decision-making and evaluation". A study in early 2009 found a total of 5,465 think tanks worldwide. Of that number, 1,777 were based in the United States and approximately 350 in Washington, DC, alone.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.